Therapix Biosciences Aktie [WKN DE: A2DQGR / ISIN: US88339A2033]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Therapix Biosciences Ltd (spons. ADRs)

04.12.19		Healthcare Stocks That Plunged To New Lows (PTGX, TRPX, MTP...) (RTTNews)
24.07.19		6 Top Gainers In Healthcare Sector (HOTH, CHMA, TRPX…) (RTTNews)
05.02.19		7 Top Gainers In Healthcare Sector (ALRN, APHA, INSY...) (RTTNews)
06.11.18		TRPX On A High, PBYI Braces For Busy Times Ahead, NVCN On Watch (RTTNews)
24.10.18		CORV Is Back, SENS' Eversense Gets Aetna Coverage, ACRX Nears FDA Decision Day (RTTNews)
23.10.18		ABBV ACHIEVES Goals, HealthStream's CFO Resigns, NTEC On Watch (RTTNews)
03.10.18		OGEN Spikes 200% In 2 Days, TRPX On A High, INO Turning Heads (RTTNews)
21.09.18		ALT Up 514% In 2 Days, CRBP Well Stocked, ACAD Soars On FDA Review (RTTNews)
05.09.18		MNKD Takes Giant Leap, REPH On Watch, ALRN To Report Study Data In Q4 (RTTNews)
30.08.18		GKOS Gains On Rival's Loss, TRPX Turns Heads, ZYNE Back On Track, SPHS On Watch (RTTNews)
21.08.18		AMRX Soars On Contract Win, TRPX Looks Ahead With Hope, ALXN To Face FDA In Feb (RTTNews)
11.06.18		Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome (PR Newswire)
06.06.18		BIIB's Alzheimer's Drug Scores Well, EXAS Heads Higher, VXRT Down But Not Out (RTTNews)
05.06.18		Therapix Biosciences Announces Enrollment of the First Patient for Clinical Trial at Assuta Medical Center for Treating Obstructive Sleep Apnea Using Cannabinoid-based Drug (PR Newswire)
01.06.18		CLSD Dims, SCPH Disappoints, ZEAL On Track, All Eyes On MRTX (RTTNews)
31.05.18		Therapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update (PR Newswire)
15.05.18		Therapix Biosciences Issues CEO's Letter to Shareholders (PR Newswire)
09.05.18		Dual-Listed Therapix to Voluntarily Delist from Tel Aviv Stock Exchange (PR Newswire)
10.04.18		ABBV's SELECT-COMPARE Hits Goals, MNLO's ATOMIK Flops, VTVT Down 63% After-Hrs (RTTNews)
09.04.18		Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program (PR Newswire)
21.03.18		FDA Nod For SGEN's Adcetris, Antibe Soars On GI Data, CHMA Empowered (RTTNews)
20.03.18		Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain (PR Newswire)
07.02.18		Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected (PR Newswire)
09.01.18		Therapix Biosciences Announces Expansion into Precision Medicine Through New Fully-Owned Subsidiary and Provides Corporate Update Today at the Biotech Showcase™ 2018 (PR Newswire)
04.12.17		Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program (PR Newswire)
21.11.17		Therapix Biosciences Spotlighted in Financial and Trade Media Outlets (PR Newswire)
10.11.17		Therapix Biosciences Plans Preclinical Study to Evaluate Opioid-Sparing Effects of Two Innovative Synthetic Cannabinoids (PR Newswire)
09.11.17		Therapix Biosciences Reports Third Quarter 2017 Financial Results and Provides Business Update (PR Newswire)
07.11.17		Therapix to Present at and Attend Investor Conferences in London (PR Newswire)
02.11.17		Therapix Biosciences Third Quarter 2017 Conference Call and Webcast Scheduled for Thursday, November 9, 2017 (PR Newswire)
02.11.17		Therapix Biosciences' Board Chairman, Ascher Shmulewitz, Appointed as Interim Chief Executive Officer (PR Newswire)
30.10.17		Live Investor Conference & Webinar: NASDAQ, NYSE and OTC companies present November 2nd (PR Newswire)
30.10.17		Live Investor Conference & Webinar: NASDAQ, NYSE and OTC companies present November 2nd (PR Newswire)
30.10.17		Therapix Biosciences Initiates Non-clinical Studies for its Antibacterial Program in Collaboration With the Weizmann Institute of Science and Tel Aviv Sourasky Medical Center (PR Newswire)
18.10.17		Therapix Biosciences and Assuta Medical Center to Initiate Clinical Trial in Obstructive Sleep Apnea (PR Newswire)
06.10.17		Therapix Signs Formulation Development and Clinical Manufacturing Agreement with Catalent for THX-TS01 (PR Newswire)
27.09.17		Therapix's First-in-Class Therapy Demonstrates Reversal of Age-Related Cognitive Impairment in Pre-Clinical Study (PR Newswire)
10.08.17		Biotech Influence on Cannabinoid-based Drug Development Leading to Latest Clinical Trials for Treatments for Chronic Disorders (PR Newswire)
10.08.17		Biotech Influence on Cannabinoid-based Drug Development Leading to Latest Clinical Trials for Treatments for Chronic Disorders (PR Newswire)
10.08.17		Therapix Biosciences Reports Second Quarter 2017 Financial Results and Provides Business Update (PR Newswire)
03.08.17		Therapix Biosciences Second Quarter 2017 Conference Call and Webcast Scheduled for Thursday, August 10, 2017 (PR Newswire)
11.07.17		Cannabinoid Market Growth Expands With Rising Influence of Pharma and Biotech Science Advancements (PR Newswire)
11.07.17		Cannabinoid Market Growth Expands With Rising Influence of Pharma and Biotech Science Advancements (PR Newswire)
11.07.17		CURE Pharmaceutical & Therapix Biosciences Signs MOU with Israel's Assuta Medical Center to Develop First-in-Class Therapeutic Products in Fields of Personalized Medicine & Cannabinoids (PR Newswire)
27.06.17		Therapix Biosciences to Ring the Nasdaq Stock Market Opening Bell on June 28 (PR Newswire)
30.05.17		Therapix Biosciences to Present at Upcoming Scientific and Investor Conferences in June (PR Newswire)
24.05.17		Therapix Biosciences Announces CEO Change (PR Newswire)
08.05.17		Therapix Biosciences and the Hannover Medical School Enter into an Investigator-initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette Syndrome (PR Newswire)
03.05.17		Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer (PR Newswire)
05.04.17		Therapix Signs Exclusive License Agreement with Yissum for Nasal Drug Delivery Technology (PR Newswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Pierer Mobility-Aktie schwach: Gehälter für Angestellte von insolventer KTM noch vor Weihnachten

UNIQA Insurance-Aktie im Plus: UNIQA plant zu expandieren und Dividenden zu erhöhen

Ethereum Kurs Prognose: ETH massiv unterbewertet! Fällt jetzt das ATH?

Bundesheer wirbt nach KTM-Insolvenz um Mitarbeiter - Pierer Mobility-Aktie im Plus

EZB wird wohl Leitzinsen senken - wie stark?

OMV-Aktie verliert: OMV kündigt Liefervertrag mit Gazprom

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	14.12.2024 21:23
Kaufwert:	EUR
	Hinzufügen Speichern